• Main page
• About the journal
• Editorial board
• Subscription
• Information for contributors
• Editorial and Peer Review
• Issues archive
• Authors
• Articles
  • By alphabet
  • By category
• Blogs and comments

The journal is included into The list of leading scientific periodicals.

The journal is included into VINITI database and is registered in Electronic scientific library.

The journal is indexed by SCOPUS, Ulrich's International Periodicals Directory.

EBSCO

https://doi.org/10.14300/mnnc.2020.15141

Non-alcoholic fatty liver diseases and diabetes in the context of diabetic liver diseases: possibilities of associated therapy

[Reviews]
Igor Veniaminovich Maev; Maksim Osadchuk; Mikhail Osadchuk; Ekaterina Dmitrievna Mironova;

The review considers non-alcoholic fatty liver disease (NAFLD) associated with diabetes mellitus (DM) in the socio-economic, etipathogenetic, prognostic and therapeutic contexts. The presence of common etiopathogenetic factors suggests that NAFLD is an independent predictor of diabetes, aggravating the course of cardiovascular diseases, micro and macroangiopathies. The progression of NAFLD against the background of diabetes requires an assessment of the effectiveness of antidiabetic drugs in achieving remission and regression of inflammatory and fibrotic changes, preventing the development of liver cirrhosis and hepatocellular carcinoma.

Download

References:
1. Neuschwander-Tetri B. A. Non-alcoholic fatty liver disease. BMC Med. 2017;15(1):45. https://doi.org/10.1186/s12916-017-0806-8
2. Eslam M., Sanyal A. J., George J., International Consensus Panel. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020;158(7):1999-2014. e1. https://doi.org/10.1053/j.gastro.2019.11.312
3. Younossi Z. M., Koenig A. B., Abdelatif D. [et al.]. Global epidemiology of nonalcoholic fatty liver disease-Metaanalytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. https://doi.org/10.1002/hep.28431
4. Snyder H. S., Sakaan S. A., March K. L. [et al.]. Nonalcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies. J. Clin. Transl. Hepatol. 2018;6(2):168-174. https://doi.org/10.14218/JCTH.2017.00050
5. Zhang M., Lin S., Wang M.-F. [et al.]. Association between NAFLD and risk of prevalent chronic kidney disease: why there is a difference between east and west? BMC Gastroenterol. 2020;20(1):139. https://doi.org/10.1186/s12876-020-01278-z
6. Williamson R. M., Price J. F., Glancy S. [et al.]. Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care. 2011;34(5):1139-1144. https://doi.org/10.2337/dc10-2229
7. Portillo-Sanchez P., Bril F., Maximos M. [et al.]. High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels. J. Clin. Endocrinol. Metab. 2015;100(6):2231-2238. https://doi.org/10.1210/jc.2015-1966
8. Armstrong M. J., Hazlehurst J. M., Parker R. [et al.]. Severe asymptomatic non-alcoholic fatty liver disease in routine diabetes care; a multi-disciplinary team approach to diagnosis and management. QJM. 2014;107(1):33-41. https://doi.org/10.1093/qjmed/hct198
9. Satapathy S. K., Sanyal A. J. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease. Semin. Liver Dis. 2015;35(3):221-235. https://doi.org/10.1055/s-0035-1562943
10. McPherson S., Hardy T., Henderson E. [et al.]. Evidence of NAFLD progression from steatosis to fibrosingsteatohepatitis using paired biopsies: implications for prognosis and clinical management. J. Hepatol. 2015;62(5):1148-1155. https://doi.org/10.1016/j.jhep.2014.11.034
11. Sumida Y., Yoneda M., Tokushige K. [et al.]. Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis. Int. J. Mol. Sci. 2020;21(6). https://doi.org/10.3390/ijms21061907
12. Younossi Z. M., Blissett D., Blissett R. [et al.]. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64(5):1577-1586. https://doi.org/10.1002/hep.28785
13. Jäger S., Jacobs S., Kröger J. [et al.]. Association between the Fatty Liver Index and Risk of Type 2 Diabetes in the EPIC-Potsdam Study. PLoS One. 2015;10(4). https://doi.org/10.1371/journal.pone.0124749
14. Singal A. K., Hasanin M., Kaif M. [et al.]. Nonalcoholic Steatohepatitis is the Most Rapidly Growing Indication for Simultaneous Liver Kidney Transplantation in the United States. Transplantation. 2016;100(3):607-612. https://doi.org/10.1097/TP.0000000000000945
15. Targher G., Byrne C. D. Clinical Review: Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J. Clin. Endocrinol. Metab. 2013;98(2):483-495. https://doi.org/10.1210/jc.2012-3093
16. Kantartzis K., Peter A., Machicao F. [et al.]. Dissociation Between Fatty Liver and Insulin Resistance in Humans Carrying a Variant of the Patatin-Like Phospholipase 3 Gene. Diabetes. 2009;58(11):2616-2623. https://doi.org/10.2337/db09-0279
17. Chu H., Duan Y., Yang L. [et al.]. Small metabolites, possible big changes: a microbiota-centered view of nonalcoholic fatty liver disease. Gut. 2019;68(2):359-370. https://doi.org/10.1136/gutjnl-2018-316307
18. Fruci B., Giuliano S., Mazza A. [et al.]. Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment. Int. J. Mol. Sci. 2013;14(11):22933-22966. https://doi.org/10.3390/ijms141122933
19. Llovet J. M., Zucman-Rossi J., Pikarsky E. [et al.]. Hepatocellular carcinoma. Nat. Rev. Dis. Primers. 2016;2:16018. https://doi.org/10.1038/nrdp.2016.18
20. Vilar-Gomez E., Martinez-Perez Y., Calzadilla-Bertot L. [et al.]. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015;149(2):367-378.e5; quiz e14-15. https://doi.org/10.1053/j.gastro.2015.04.005
21. Angulo P., Kleiner D. E., Dam-Larsen S. [et al.]. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015;149(2):389-397.e10. https://doi.org/10.1053/j.gastro.2015.04.043
22. Singh S., Allen A. M., Wang Z. [et al.]. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin. Gastroenterol. Hepatol. 2015;13(4):643-654. e1-9; quiz e39-40. https://doi.org/10.1016/j.cgh.2014.04.014
23. Chalasani N., Younossi Z., Lavine J. E. [et al.]. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357. https://doi.org/10.1002/hep.29367
24. Choudhary N. S., Saraf N., Saigal S. [et al.]. Rapid Reversal of Liver Steatosis With Life Style Modification in Highly Motivated Liver Donors. J. Clin. Exp. Hepatol. 2015;5(2):123-126. https://doi.org/10.1016/j.jceh.2015.04.002
25. Hallsworth K., Thoma C., Hollingsworth K. G. [et al.]. Modified high-intensity interval training reduces liver fat and improves cardiac function in non-alcoholic fatty liver disease: a randomized controlled trial. Clin. Sci. 2015;129(12):1097-1105. https://doi.org/10.1042/CS20150308
26. Romero-Gómez M., Zelber-Sagi S., Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J. Hepatol. 2017;67(4):829-846. https://doi.org/10.1016/j.jhep.2017.05.016
27. Davies M. J., D’Alessio D. A., Fradkin J. [et al.]. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669-2701. https://doi.org/10.2337/dci18-0033
28. Watanabe S., Hashimoto E., Ikejima K. [et al.]. Evidencebased clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatol. Res. 2015;45(4):363-377. https://doi.org/10.1111/hepr.12511
29. Younossi Z., Tacke F., Arrese M. [et al.]. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology. 2019;69(6):2672-2682. https://doi.org/10.1002/hep.30251
30. Tang A., Rabasa-Lhoret R., Castel H. [et al.]. Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial. Diabetes Care. 2015;38(7):1339-1346. https://doi.org/10.2337/dc14-2548
31. Goh GB-B., Pagadala M. R., Dasarathy J. [et al.]. Diabetes Mellitus, Insulin, Sulfonylurea and Advanced Fibrosis in Non- Alcoholic Fatty Liver Disease. Published online 2014. https://doi.org/10.4172/2155-6156.1000410
32. Zhou G., Myers R., Li Y. [et al.]. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 2001;108(8):1167-1174. https://doi.org/10.1172/JCI13505
33. Wu H., Esteve E., Tremaroli V. [et al.]. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat. Med. 2017;23(7):850-858. https://doi.org/10.1038/nm.4345
34. Huang M.-Y., Chung C.-H., Chang W.-K. [et al.]. The role of thiazolidinediones in hepatocellular carcinoma risk reduction: a population-based cohort study in Taiwan. Am. J. Cancer Res. 2017;7(7):1606-1616.
35. Van Wagner L. B., Rinella M. E. The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. Therap. Adv. Gastroenterol. 2011;4(4):249-263. https://doi.org/10.1177/1756283X11403809
36. Musso G., Cassader M., Paschetta E. [et al.]. Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis. JAMA Intern. Med. 2017;177(5):633-640. https://doi.org/10.1001/jamainternmed.2016.9607
37. Chalasani N., Younossi Z., Lavine J. E. [et al.]. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005-2023. https://doi.org/10.1002/hep.25762
38. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 2016;64(6):1388-1402. https://doi.org/10.1016/j.jhep.2015.11.004
39. Viscoli C. M., Inzucchi S. E., Young L. H. [et al.]. Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial. J. Clin. Endocrinol. Metab. 2017;102(3):914-922. https://doi.org/10.1210/jc.2016-3237
40. Abrahami D., Douros A., Yin H. [et al.]. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. BMJ. 2018;363:k4880. https://doi.org/10.1136/bmj.k4880
41. Abrahami D., Douros A., Yin H. [et al.]. Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. BMJ. 2018;360:k872. https://doi.org/10.1136/bmj.k872
42. Sumida Y., Yoneda M., Tokushige K. [et al.]. Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis. Int. J. Mol. Sci. 2020;21(6). https://doi.org/10.3390/ijms21061907
43. Ao N., Yang J., Wang X. [et al.]. Glucagon-like peptide-1 preserves non-alcoholic fatty liver disease through inhibition of the endoplasmic reticulum stress-associated pathway. Hepatol. Res. 2016;46(4):343-353. https://doi.org/10.1111/hepr.12551
44. Armstrong M. J., Gaunt P., Aithal G. P. [et al.]. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679-690. https://doi.org/10.1016/S0140-6736(15)00803-X
45. Eguchi Y., Kitajima Y., Hyogo H. [et al.]. Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). Hepatol. Res. 2015;45(3):269-278. https://doi.org/10.1111/hepr.12351
46. Cusi K., Sattar N., García-Pérez L.-E. [et al.]. Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme. Diabet. Med. 2018;35(10):1434-1439. https://doi.org/10.1111/dme.13697
47. Gerstein H. C., Colhoun H. M., Dagenais G. R. [et al.]. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121-130. https://doi.org/10.1016/S0140-6736(19)31149-3
48. Marso S. P., Bain S. C., Consoli A. [et al.]. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N. Engl. J. Med. 2016;375(19):1834-1844. https://doi.org/10.1056/NEJMoa1607141
49. Newsome P., Francque S., Harrison S. [et al.]. Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity. Aliment. Pharmacol. Ther. 2019;50(2):193-203. https://doi.org/10.1111/apt.15316
50. Pratley R. E., Aroda V. R., Lingvay I. [et al.]. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275-286. https://doi.org/10.1016/S2213-8587(18)30024-X
51. Camastra S., Astiarraga B., Tura A. [et al.]. Effect of exenatide on postprandial glucose fluxes, lipolysis, and ß-cell function in non-diabetic, morbidly obese patients. Diabetes Obes. Metab. 2017;19(3):412-420. https://doi.org/10.1111/dom.12836
52. Seko Y., Nishikawa T., Umemura A. [et al.]. Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1-3 fibrosis. Diabetes Metab. Syndr. Obes. 2018;11:835-843. https://doi.org/10.2147/DMSO.S184767
53. Shibuya T., Fushimi N., Kawai M. [et al.]. Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study. Diabetes Obes. Metab. 2018;20(2):438-442. https://doi.org/10.1111/dom.13061
54. Ito D., Shimizu S., Inoue K. [et al.]. Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial. Diabetes Care. 2017;40(10):1364-1372. https://doi.org/10.2337/dc17-0518
55. Yang Z.-X., Shen W., Sun H. Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease. Hepatol. Int. 2010;4(4):741-748. https://doi.org/10.1007/s12072-010-9202-6
56. Tanaka N., Kimura T., Fujimori N. [et al.]. Current status, problems, and perspectives of non-alcoholic fatty liver disease research. World J. Gastroenterol. 2019;25(2):163-177. https://doi.org/10.3748/wjg.v25.i2.163

Keywords: non-alcoholic fatty liver disease, diabetes mellitus, antidiabetic drugs, metformin, thiazolidinediones, glucagon-like peptide 1 receptor agonists, dipeptidyl peptidase 4 inhibitors, sodium/glucose cotransporter 2 nhibitors